MCID: SCL009
MIFTS: 54

Sclerosing Cholangitis

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Sclerosing Cholangitis

MalaCards integrated aliases for Sclerosing Cholangitis:

Name: Sclerosing Cholangitis 12 76 15
Primary Sclerosing Cholangitis 73
Cholangitis, Sclerosing 73
Fibrosing Cholangitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14268
ICD10 33 K83.0
MeSH 44 D015209
SNOMED-CT 68 4032000

Summaries for Sclerosing Cholangitis

MalaCards based summary : Sclerosing Cholangitis, also known as primary sclerosing cholangitis, is related to sclerosing cholangitis, neonatal and cholangitis, primary sclerosing, and has symptoms including icterus An important gene associated with Sclerosing Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and Selenium Micronutrient Network. The drugs Vancomycin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and eye, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder... more...

Related Diseases for Sclerosing Cholangitis

Diseases in the Sclerosing Cholangitis family:

Cholangitis, Primary Sclerosing Secondary Sclerosing Cholangitis

Diseases related to Sclerosing Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 281)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 34.3 CLDN1 DCDC2
2 cholangitis, primary sclerosing 32.3 ABCB4 ALB BPI CFTR CTSG FUT2
3 cholangitis 30.8 ABCB11 ABCB4 ALB CFTR CLDN1 DCDC2
4 primary biliary cirrhosis 30.8 ABCB4 ALB GGT1 NR1H4
5 ulcerative colitis 30.8 BPI MPO TNF
6 inflammatory bowel disease 30.2 ALB BPI CTSG HLA-B HLA-DRB1 MPO
7 acquired immunodeficiency syndrome 30.2 ALB HLA-B TNF
8 pure red-cell aplasia 30.1 ALB HLA-B HLA-DRB1
9 obstructive jaundice 30.0 ALB GGT1 GPBAR1 TNF
10 liver disease 30.0 ABCB11 ABCB4 ALB GGT1 NR1H4 TNF
11 cholestasis 29.9 ABCB11 ABCB4 GGT1 NR1H4 NR1I2
12 gastroenteritis 29.9 ALB FUT2 TNF
13 cystic fibrosis 29.9 BPI CFTR CTSG MPO
14 psoriatic arthritis 29.9 HLA-B HLA-C HLA-DRB1 TNF
15 peritonitis 29.9 ALB MPO TNF
16 atp8b1 deficiency 29.8 ABCB11 NR1H4
17 suppurative cholangitis 29.8 ABCB4 MPO TNF
18 cholelithiasis 29.7 ABCB4 ALB NR1H4
19 bronchiectasis 29.4 BPI CFTR CTSG MPO
20 bile duct disease 29.2 ABCB11 ABCB4 ALB GGT1 GPBAR1 NR1H4
21 biliary tract disease 29.1 ABCB11 ABCB4 ALB GGT1 GPBAR1 NR1H4
22 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.9
23 secondary sclerosing cholangitis 12.6
24 igg4-related sclerosing cholangitis 12.4
25 pancreatitis, sclerosing cholangitis, and sicca complex 12.4
26 isolated neonatal sclerosing cholangitis 12.2
27 bile duct cancer 11.7
28 cholangiocarcinoma 11.7
29 colitis 10.9
30 pancreatitis 10.7
31 primary biliary cholangitis 10.7
32 autoimmune pancreatitis 10.7
33 hepatitis 10.7
34 autoimmune hepatitis 10.7
35 biliary cirrhosis, primary, 1 10.7
36 crohn's disease 10.5
37 colorectal cancer 10.4
38 langerhans cell histiocytosis 10.3
39 hemolytic anemia 10.3
40 histiocytosis 10.3
41 intrahepatic cholangiocarcinoma 10.3
42 retroperitoneal fibrosis 10.3
43 anemia, autoimmune hemolytic 10.3
44 ichthyosis 10.3
45 postherpetic neuralgia 10.3 HLA-B HLA-DRB1
46 hepatocellular carcinoma 10.2
47 lymphoma 10.2
48 idiopathic inflammatory myopathy 10.2 HLA-B HLA-DRB1
49 drug reaction with eosinophilia and systemic symptoms 10.2 HLA-B TNF
50 cryptosporidiosis 10.2

Graphical network of the top 20 diseases related to Sclerosing Cholangitis:



Diseases related to Sclerosing Cholangitis

Symptoms & Phenotypes for Sclerosing Cholangitis

UMLS symptoms related to Sclerosing Cholangitis:


icterus

GenomeRNAi Phenotypes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.2 MPO
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.2 NR1H4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.2 CTSG HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.2 NR1H4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.2 HLA-B HLA-C NR1H4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.2 HLA-B HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.2 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.2 MPO
9 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.2 CTSG
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.2 GGT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.2 GGT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.2 CTSG HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.2 HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.2 MPO
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.2 NR1H4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.2 CTSG NR1H4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.2 HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.2 GGT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.2 MPO
20 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.2 HLA-B HLA-C
21 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.2 MPO
22 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.2 HLA-B HLA-C
23 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.2 HLA-C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.2 CTSG
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.2 MPO
26 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.2 HLA-B HLA-C
27 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.2 MPO
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.2 CTSG
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.2 HLA-C
30 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.2 MPO
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.2 HLA-B HLA-C GGT1 MPO NR1H4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.2 MPO
33 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.2 HLA-B HLA-C
34 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.2 HLA-C
35 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.2 NR1H4

MGI Mouse Phenotypes related to Sclerosing Cholangitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 ABCB11 ABCB4 ALB CFTR CLDN1 GGT1
2 liver/biliary system MP:0005370 9.28 ABCB11 ABCB4 ALB CFTR CTSG GPBAR1

Drugs & Therapeutics for Sclerosing Cholangitis

Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 14969 441141
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Prednisone Approved, Vet_approved Phase 4,Not Applicable 53-03-2 5865
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antibiotics, Antitubercular Phase 4,Phase 2,Not Applicable
15 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable
17 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
18 Immunologic Factors Phase 4,Phase 2,Phase 1
19 Hormone Antagonists Phase 4,Phase 1
20 Immunoglobulin G Phase 4,Phase 1,Phase 2,Not Applicable
21 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable
22 Antirheumatic Agents Phase 4,Phase 1,Phase 2
23 Hormones Phase 4,Phase 1
24 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
25 glucocorticoids Phase 4,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1
27 Bile Acids and Salts Phase 4,Phase 2,Phase 1
28 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
29 Topoisomerase Inhibitors Phase 4
30 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
31 Renal Agents Phase 4
32 Cytochrome P-450 Enzyme Inhibitors Phase 4
33 Anti-Infective Agents, Urinary Phase 4
34 Antitubercular Agents Phase 4
35 Methylprednisolone acetate Phase 4
36 Antineoplastic Agents, Hormonal Phase 4
37 Prednisolone acetate Phase 4
38
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
39
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3,Phase 1 128-13-2 31401
40 Lipid Regulating Agents Phase 3,Phase 1,Phase 2
41 Antimetabolites Phase 3,Phase 1,Phase 2,Not Applicable
42 Hypolipidemic Agents Phase 3,Phase 1,Phase 2
43 Cholagogues and Choleretics Phase 2, Phase 3,Phase 1
44
Dobutamine Approved Phase 2 34368-04-2 36811
45
Norepinephrine Approved Phase 2 51-41-2 439260
46
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
47
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
48
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
49
Sulfasalazine Approved Phase 2 599-79-1 5353980 5359476
50
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
3 Leflunomide for Maintenance of Remission in IgG4 Related Disease Recruiting NCT02703194 Phase 4 Prednisone;Leflunomide
4 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4 Vancomycin
5 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
6 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
7 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
8 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
9 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
10 Vancomycin for Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
11 Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
12 Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis Unknown status NCT01690845 Phase 2
13 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
14 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Completed NCT02424175 Phase 1, Phase 2
15 Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
16 Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Completed NCT02177136 Phase 2 OCA;Placebo
17 Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
18 Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
19 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
20 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
21 Rituximab in IgG4-RD: A Phase 1-2 Trial Completed NCT01584388 Phase 1, Phase 2 Rituximab
22 Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Recruiting NCT01688024 Phase 2 Mitomycin C;Normal saline
23 A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Recruiting NCT02239211 Phase 2 BTT1023
24 A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) Recruiting NCT03394781 Phase 2 DUR-928
25 Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis Recruiting NCT03561584 Phase 2 Sulfasalazine;Placebo
26 A POC and Dose-Ranging Study of HTD1801 in PSC Patients Recruiting NCT03333928 Phase 2 HTD1801;Placebo
27 An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis Recruiting NCT03359174 Phase 2 All-trans retinoic acid
28 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
29 Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis Active, not recruiting NCT03516006 Phase 1, Phase 2 UCMSC;UDCA
30 A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Active, not recruiting NCT02978339 Phase 1, Phase 2 Curcumin
31 Safety, Tolerability, and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Active, not recruiting NCT02943460 Phase 2 GS-9674;Placebo to match GS-9674
32 A Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis Not yet recruiting NCT02780752 Phase 1, Phase 2 hymecromone
33 Vidofludimus Calcium for Primary Sclerosing Cholangitis Not yet recruiting NCT03722576 Phase 2 Vidofludimus calcium
34 A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC) Not yet recruiting NCT03678480 Phase 2 HTD1801;Ursodeoxycholic Acid
35 A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH Not yet recruiting NCT02997878 Phase 1, Phase 2
36 Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC) Terminated NCT00953615 Phase 2 Thalidomide
37 Pilot Study of Fenofibrate for PSC Terminated NCT01142323 Phase 1, Phase 2 fenofibrate
38 The Value of CT Cholangiography in Primary Sclerosing Cholangitis Withdrawn NCT00588458 Phase 2
39 Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Completed NCT01322386 Phase 1 Vancomycin
40 Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) Completed NCT00955149 Phase 1 Erlotinib (Tarceva)
41 Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Completed NCT01088607 Phase 1 ursodeoxycholic acid (UDCA)
42 A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis Completed NCT01085760 Phase 1 Vancomycin;Vancomycin;Metronidazole;Metronidazole;Vancomycin
43 Minocycline in Primary Sclerosing Cholangitis (PSC) Completed NCT00630942 Phase 1 Minocycline
44 A Pilot Study of Xifaxan to Treat Patients With PSC Completed NCT01695174 Phase 1 Xifaxan
45 Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Completed NCT00004842 Phase 1 budesonide
46 Evaluation of DHA for the Treatment of PSC Completed NCT00325013 Phase 1 Docosahexaenoic Acid (DHA)
47 Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis Completed NCT01456468 Phase 1 Oral all-trans retinoic acid (ATRA)
48 A Study of HTD1801 in Healthy Subjects Completed NCT03099603 Phase 1 HTD1801
49 Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT Completed NCT01879735 Phase 1 11C-CSar;ICG
50 Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Recruiting NCT02137668 Phase 1 Oral Vancomycin

Search NIH Clinical Center for Sclerosing Cholangitis

Genetic Tests for Sclerosing Cholangitis

Anatomical Context for Sclerosing Cholangitis

MalaCards organs/tissues related to Sclerosing Cholangitis:

41
Liver, Skin, Eye, T Cells, Colon, Testes, Bone

Publications for Sclerosing Cholangitis

Articles related to Sclerosing Cholangitis:

(show top 50) (show all 1543)
# Title Authors Year
1
Clinical guidelines for primary sclerosing cholangitis 2017. ( 29951926 )
2018
2
The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. ( 29435321 )
2018
3
Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 29378308 )
2018
4
Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. ( 29862092 )
2018
5
Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis. ( 29922759 )
2018
6
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. ( 29377235 )
2018
7
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )
2018
8
Lack of Correlation of Liver Tests With Fibrosis Stage at Diagnosis in Pediatric Primary Sclerosing Cholangitis. ( 29356767 )
2018
9
A promising medium-term follow-up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis? ( 29316057 )
2018
10
The role of MRI and ERCP in the evaluation of disease activity and severity in primary sclerosing cholangitis. ( 29901259 )
2018
11
Peribiliary Cysts presenting as Primary Sclerosing Cholangitis. ( 29432923 )
2018
12
Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314130 )
2018
13
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
14
Differential diagnosis of cholangiocarcinoma and IgG4-related sclerosing cholangitis by fluorescence inA situ hybridization using transpapillary forceps biopsy specimens. ( 29532638 )
2018
15
Endoscopic management of primary sclerosing cholangitis. ( 29883229 )
2018
16
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. ( 29808485 )
2018
17
Kindler syndrome in a patient with colitis and primary sclerosing cholangitis: coincidence or association? ( 29634879 )
2018
18
Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: a systematic analysis of 12 cases. ( 29313399 )
2018
19
Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. ( 29781738 )
2018
20
Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. ( 29851098 )
2018
21
Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. ( 29802947 )
2018
22
The significance of serum IgG<sub>4</sub>and CA19-9, autoantibodies in diagnosis and differential diagnosis of IgG<sub>4</sub>-related sclerosing cholangitis. ( 29272982 )
2018
23
Secondary sclerosing cholangitis in critically ill patients after a traffic accident-a new entity that should be considered in death classification. ( 29484493 )
2018
24
Update in the Care and Management of Patients with Primary Sclerosing Cholangitis. ( 29886518 )
2018
25
Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review. ( 29976215 )
2018
26
Sclerosing Cholangitis Like Changes on Magnetic Resonance Cholangiography in Patients with Drug Induced Liver Injury. ( 29966706 )
2018
27
Anesthetic Care of 2 Siblings With Neonatal Ichthyosis and Sclerosing Cholangitis Syndrome: Case Reports. ( 29738332 )
2018
28
Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. ( 29852184 )
2018
29
Right Sided Colonic Juvenile Polyp (polyps) in Pediatric Primary Sclerosing Cholangitis Patients. ( 29931365 )
2018
30
Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication. ( 29278002 )
2018
31
Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. ( 29411404 )
2018
32
Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study. ( 29301479 )
2018
33
An Imaging Biomarker for Assessing Hepatic Function in Patients with Primary Sclerosing Cholangitis. ( 29775791 )
2018
34
Primary sclerosing cholangitis is associated with abnormalities in CFTR. ( 29807875 )
2018
35
Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis. ( 29333790 )
2018
36
High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. ( 29378311 )
2018
37
Association between smoking and risk of primary sclerosing cholangitis: A systematic review and meta-analysis. ( 29881604 )
2018
38
The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. ( 29882252 )
2018
39
Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis. ( 29314124 )
2018
40
Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. ( 29321484 )
2018
41
No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. ( 29803836 )
2018
42
Quality of life and primary sclerosing cholangitis: the business of defining what counts. ( 29315689 )
2018
43
The Immunobiology of RANKL and Myeloid Derived Suppressor Cell Activation in IgG4-related Sclerosing Cholangitis. ( 29774578 )
2018
44
Autoimmune Hepatitis, Sclerosing Cholangitis, and Autoimmune Sclerosing Cholangitis or Overlap Syndrome. ( 30266157 )
2018
45
The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. ( 30136315 )
2018
46
Autoimmune Hepatitis and Autoimmune Hepatitis Overlap With Sclerosing Cholangitis: Immunophenotype Markers in Children and Adolescents. ( 29045346 )
2018
47
Type-1 Seronegative Autoimmune Pancreatitis: A Rare Case of Autoimmune Pancreatitis with Sclerosing Cholangitis and Hashimoto's Disease. ( 30027016 )
2018
48
IgG4 related autoimmune pancreatitis and sclerosing cholangitis. ( 30457561 )
2018
49
Massive hemobilia following plastic stent removal in common bile duct cancer associated with primary sclerosing cholangitis (with video). ( 30056613 )
2018
50
Rare case of idiopathic sclerosing cholangitis, which was difficult to distinguish from cholangiocarcinoma: A case report. ( 30546416 )
2018

Variations for Sclerosing Cholangitis

Expression for Sclerosing Cholangitis

Search GEO for disease gene expression data for Sclerosing Cholangitis.

Pathways for Sclerosing Cholangitis

GO Terms for Sclerosing Cholangitis

Cellular components related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.63 CFTR CTSG HLA-B HLA-C HLA-DRB1 TNF
2 azurophil granule lumen GO:0035578 9.61 BPI CTSG MPO
3 recycling endosome membrane GO:0055038 9.54 CFTR HLA-B HLA-C
4 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-B HLA-C HLA-DRB1
5 MHC class I protein complex GO:0042612 9.4 HLA-B HLA-C
6 extracellular exosome GO:0070062 9.36 ABCB11 ABCB4 ALB BPI CTSG FUT2
7 intercellular canaliculus GO:0046581 9.32 ABCB11 ABCB4
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-B HLA-C HLA-DRB1

Biological processes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.88 BPI CTSG HLA-B HLA-C MPO
2 response to lipopolysaccharide GO:0032496 9.71 CLDN1 CTSG GGT1 MPO
3 interferon-gamma-mediated signaling pathway GO:0060333 9.67 HLA-B HLA-C HLA-DRB1
4 immune response GO:0006955 9.63 BPI CTSG HLA-B HLA-C HLA-DRB1 TNF
5 antigen processing and presentation GO:0019882 9.54 HLA-B HLA-C HLA-DRB1
6 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.51 HLA-B HLA-C
7 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.5 CFTR HLA-DRB1 NR1H4
8 xenobiotic transport GO:0042908 9.46 ABCB4 NR1I2
9 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.43 HLA-B HLA-C
10 negative regulation of interleukin-6 production GO:0032715 9.43 BPI NR1H4 TNF
11 defense response to bacterium GO:0042742 9.35 BPI CTSG MPO NR1H4 TNF
12 negative regulation of growth of symbiont in host GO:0044130 8.8 CTSG MPO TNF

Molecular functions related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.33 ABCB11 ABCB4 CFTR
2 thyroid hormone receptor activity GO:0004887 9.26 NR1H4 NR1I2
3 peptide antigen binding GO:0042605 9.13 HLA-B HLA-C HLA-DRB1
4 bile acid receptor activity GO:0038181 8.62 GPBAR1 NR1H4

Sources for Sclerosing Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....